PD 173074: Nanomolar FGFR1/VEGFR2 Inhibition for Cancer Research

Executive Summary: PD 173074 is a potent, ATP-competitive tyrosine kinase inhibitor, selectively targeting FGFR1 (IC50 ≈ 21.5 nM) and VEGFR2 (autophosphorylation inhibition at 100–200 nM) (source: product_spec). It shows approximately 1000-fold selectivity over kinases such as PDGFR, c-Src, EGFR, and insulin receptor (source: product_spec). The compound blocks FGF-2-mediated proliferation and angiogenesis in vitro and in vivo (source: DOI). PD 173074 reverses ABCB1/ABCC10-mediated multidrug resistance at higher concentrations (source: product_spec). APExBIO supplies PD 173074 (SKU A8253) as a solid, soluble in DMSO and ethanol, with recommended storage at 4°C (source: product_spec).

Biological Rationale

The fibroblast growth factor (FGF) signaling pathway orchestrates cell proliferation, differentiation, and angiogenesis. FGFR1 is a critical regulator of early adipogenic events and proliferation in human preadipocytes (source: DOI). FGF-1 and FGF-2 stimulate preadipocyte commitment and differentiation primarily via FGFR1 activation. In cancer biology, aberrant FGFR and VEGFR signaling contributes to tumor angiogenesis, growth, and metastasis (source: internal). Pharmacological inhibition of FGFR1, as achieved with agents like PD 173074, interrupts these pathological processes, providing a tractable approach for both metabolic and oncological research.

Mechanism of Action of PD 173074

PD 173074 is a small molecule, ATP-competitive inhibitor. It binds to the ATP-binding site of FGFR1, blocking receptor autophosphorylation and downstream signaling. The molecule also inhibits VEGFR2 autophosphorylation at higher concentrations. This dual inhibition disrupts FGF- and VEGF-driven biological processes, notably cell proliferation and angiogenesis (source: product_spec). Its selectivity profile demonstrates minimal off-target activity against kinases such as PDGFR, c-Src, EGFR, and the insulin receptor, with over 1000-fold selectivity for FGFR1/VEGFR2 (source: product_spec). By antagonizing FGF-2-mediated effects, PD 173074 serves as a benchmark tool for dissecting FGFR signaling in research settings (source: internal).

Evidence & Benchmarks

• PD 173074 inhibits FGFR1 kinase activity with an IC50 of approximately 21.5 nM (source: product_spec).
• VEGFR2 autophosphorylation is suppressed at 100–200 nM concentrations in cellular assays (source: product_spec).
• FGFR-specific inhibition blocks FGF-1-induced proliferation and priming in human preadipocytes, as demonstrated in primary cell and SGBS models (source: DOI).
• PD 173074 reverses ABCB1/ABCC10-mediated multidrug resistance in cancer cells at micromolar concentrations (source: product_spec).
• No apparent toxicity observed in animal models at effective doses (source: product_spec).

This article expands on the application protocols discussed in PD 173074 (SKU A8253): Reliable FGFR1/VEGFR2 Inhibition for Biomedical Research by providing additional molecular selectivity data and evidence from adipogenesis studies. For a more detailed mechanistic perspective, see PD 173074: Selective FGFR1 Inhibitor for Precise FGFR Signaling Pathway Inhibition, which this article extends with practical dosing and solubility insights.

Applications, Limits & Misconceptions

PD 173074 is widely used in cancer research, metabolic disease studies, and vascular biology. Key applications include:

• Dissection of FGFR and VEGFR signaling pathways in cell proliferation, migration, and angiogenesis assays.
• Evaluation of FGF-1/FGF-2-mediated effects in adipogenesis and preadipocyte differentiation.
• Investigation of tumor growth inhibition and anti-angiogenic activity in xenograft and neovascularization models.
• Reversal of multidrug resistance mediated by ABCB1/ABCC10 transporters.

PD 173074 is not suitable for kinase targets outside the FGFR/VEGFR family due to its high selectivity. Its efficacy in water-based systems is limited by poor aqueous solubility, requiring DMSO or ethanol for dissolution (source: product_spec). Long-term storage of solutions is not recommended.

Common Pitfalls or Misconceptions

• Assuming activity against non-FGFR, non-VEGFR kinases: PD 173074 is >1000-fold selective; off-target inhibition is negligible (source: product_spec).
• Using aqueous buffers for dissolution: The compound is insoluble in water; DMSO or ethanol with sonication is required (source: product_spec).
• Expecting efficacy at sub-nanomolar concentrations: Effective inhibition occurs in the nanomolar to low micromolar range, depending on the target and application (source: product_spec).
• Assuming reversible multidrug resistance at all concentrations: MDR reversal is observed at higher (micromolar) concentrations only.
• Overlooking the need for prompt solution use: Solutions are unstable over extended periods and should be used shortly after preparation.

Workflow Integration & Parameters

Protocol Parameters

• kinase inhibition assay | 21.5 nM (FGFR1 IC50) | in vitro enzymatic/cell assay | Defines PD 173074's potency; enables benchmarking in kinase selectivity screens | product_spec
• cell culture proliferation inhibition | 10–100 nM | human preadipocytes, cancer cell lines | Suppresses FGF-2-induced proliferation and differentiation | DOI
• multidrug resistance reversal | 1–10 μM | ABCB1/ABCC10-expressing cancer cells | Reverses MDR phenotype in vitro and in vivo | product_spec
• animal dosing (i.p.) | 1–2 mg/kg/day | mouse models | Achieves robust pathway inhibition without toxicity | product_spec
• solution prep | ≥26.18 mg/mL in DMSO; ≥108.4 mg/mL in ethanol (ultrasonic) | stock solution | Ensures solubility for experimental use; avoid water | product_spec
• storage | 4°C (solid), avoid long-term storage of solutions | all applications | Maintains compound integrity | product_spec

For additional optimization strategies and troubleshooting, this scenario-driven guide offers evidence-based insights into cell viability and cytotoxicity assay design with PD 173074.

Conclusion & Outlook

PD 173074 (A8253) enables highly selective, nanomolar inhibition of FGFR1 and VEGFR2, facilitating precise dissection of FGF/VEGF signaling in cancer, angiogenesis, and adipogenesis research. Its robust selectivity and low toxicity profile make it a gold-standard tool for pathway validation and preclinical studies (source: DOI). As research progresses, PD 173074 will remain central to studies investigating FGFR-driven disease mechanisms and therapeutic strategies. For detailed product specifications and ordering, refer to APExBIO's PD 173074 page.